Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
holding | HLVX | Common Stock | 500K | Apr 28, 2022 | See Explanation of Responses | F1 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
holding | HLVX | Warrant (Right to Buy) | Apr 28, 2022 | Common Stock | 3.5M | $0.00 | See Explanation of Responses | F1 |
Id | Content |
---|---|
F1 | Takeda Pharmaceutical Company Ltd's beneficial ownership of the reported securities is comprised of 500,000 shares of Common Stock and a Warrant to purchase 3,500,000 shares of Common Stock; each held by Takeda Vaccines, Inc., an indirect wholly-owned subsidiary of Takeda Pharmaceutical Company Limited. Takeda Vaccines, Inc. is owned directly by Takeda Pharmaceuticals U.S.A., Inc., which is owned directly by both Takeda Pharmaceutical Company Limited (72.70%) and Takeda Pharmaceuticals International AG (27.30%). Takeda Pharmaceuticals International AG is a wholly-owned direct subsidiary of Takeda Pharmaceutical Company Limited. |